Chronic myeloid leukemia can be effectively treated with BCR-ABL1 tyrosine kinase inhibitors. However, BCR-ABL1 mutations can develop and cause secondary resistance to these inhibitors. | Finding the right BCR-ABL1 tyrosine kinase inhibitor A case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib